
People threatened by accidental exposure to foods they’re allergic to may have a new weapon of defense: On Friday, the U.S. Food and Drug Administration expanded the use of the asthma drug Xolair to help prevent anaphylactic reactions. Xolair (omalizumab) is an injected drug and is not meant as a substitute for EpiPens or other anaphylaxis rescue remedies, the agency stressed. Instead, “Xolair is intended for repeated use to reduce the risk of allergic reactions” if and when they occur, the FDA explained in a news release. Made by Genentech, Xolair is the first medication approved to help reduce allergic reactions to multiple types of foods, the agency noted. Xolair was first approved in 2003 for the treatment of moderate to severe allergic asthma. It’s also been approved to treat a skin rash called urticaria, as well as chronic rhinosinusitis with nasal polyps in certain patients. The medication is a monoclonal antibody that works by binding to and blocking the function of immunoglobulin E (IgE), the antibody that helps trigger an allergic reaction. “This newly approved use for Xolair will provide a treatment option to reduce the risk of harmful allergic reactions among certain patients with IgE-mediated food allergies,” Dr. Kelly Stone said in the news release. She’s associate director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug… read on > read on >